Thermo Fisher and Symphogen continue work to support the development of innovative cancer treatments through optimization of protein characterization and quality monitoring mass spectrometry workflows
Thermo Fisher Scientific and Symphogen, an affiliate of and the antibody center of excellence within the international pharmaceutical company, Servier, on 29 Oct 2020 announced the extension of a strategic collaboration to deliver industry-proven, innovative characterization and quality control workflows for the simplified analysis of complex therapeutic proteins to advance biopharmaceutical discovery and development.
"Through our collaboration with Symphogen, we can provide the biopharmaceutical industry with proven characterization methods that can be translated into transferable, routine, compliance-ready solutions to boost drug discovery and development," said Eric Grumbach, director, biopharma/pharma, chromatography and mass spectrometry, Thermo Fisher Scientific.
Dan Bach Kristensen, principal investigator, Symphogen, said, "Over the past two years, the advanced characterization and lead selection studies of several hundred mAb samples enabled by the Q Exactive Plus Orbitrap LC-MS/MS system has allowed us to simplify our analytical strategies, ultimately accelerating our pipeline. Extending our collaboration with Thermo Fisher is the natural way forward to continue driving innovation in the discovery and development of highly differentiated cancer therapeutics."